Submission platforms organize documents, comments, owners, eCTD validation, and package assembly.
MODE: READ_ONLY_EXPORTS
STATUS: CONTRADICTION_REVIEW
Enterprise Pharma Readiness Engine
Find the weak spot before inspection does.
VIXAR walks your team through four steps: answer five questions, scan a workbook, review one room photo, then see what to fix next.
FDA-first review path
Start with a sanitized sample tracker. Move real evidence behind authorized access.
1. Answer five questions
2. Scan a workbook
3. Review one room photo
CORE_TOPOLOGY
CONTRADICTION_REVIEW: WORKBOOK + PROFILE
DOCTRINE_LINKS: TRACEABLE
[ Start Here ]
Do one step at a time.
If you are new, start at step one. Each step creates evidence for the next screen.[ FDA Elsa 4.0 / HALO ]
The reviewer got smarter. Your evidence map has to get sharper.
FDA announced Elsa 4.0 and HALO on May 6, 2026. HALO consolidates 40+ application and submission data sources; Elsa adds custom agents, document generation, quantitative analysis, text extraction, and optimized search.
Elsa sits on the review side.
VIXAR maps your internal evidence.
Read the FDA release
Elsa 4.0 + HALO ยท official source
[ Pre-eCTD Evidence Readiness ]
Submission software assembles the file. VIXAR exposes whether the evidence survives.
Before a team drafts, validates, publishes, or submits, the underlying manufacturing and QA evidence still has to reconcile. VIXAR checks that layer first.VIXAR reviews workbook exports, clean-room image evidence, operator context, SOR contradictions, owners, timing, and doctrine-linked risk before the package makes it look clean.
Start with files your teams already have. VIXAR does not require replacing Veeva, Lorenz, SharePoint, Box, MES, LIMS, QMS, or calibration systems.
If FDA-side AI can cross-reference submission data, your internal contradiction map has to exist before the reviewer asks why the evidence disagrees.
T-30Contradiction SweepWorkbook exports, SOR relationships, open owners.
T-14Evidence ReviewClean-room image, tracker state, doctrine tags.
T-7Owner ClosureNamed action owner and proof needed to close.
T-3Executive BriefEvidence-ready state, unresolved issues, next action.
T-0Submission SupportPass the evidence map into the regulatory workspace.
[ US FDA First ]
Built for U.S. pharma teams with quiet global awareness.
VIXAR is the product layer. Day Zero is the field methodology behind it, shaped first around U.S. life-sciences manufacturing, FDA-facing quality work, and inspection pressure.
Primary market: U.S. pharma.
Engineering lineage includes Severus Engineering pharmaceutical project work, including Eli Lilly exposure. The map shows U.S. FDA focus first, with light indicators for international operating contexts.
US FDA
Europe
ICH
Sites
U.S. FDA
primary focus
The lead standard for the pipeline: U.S. audit trail, traceability, data integrity, and inspection-ready evidence language.
Open U.S. 21 CFRKept quiet on the page, but useful when a buyer has European manufacturing, partner, or affiliate expectations.
Open EU GMP sourceSupports API GMP and quality-system conversations when U.S. buyers need international alignment.
Open ICH quality guidelinesUseful when a U.S. pharma buyer also touches device, combination-product, or supplier workflows.
Open ISO 13485 page[ Why teams trust it ]
Serious enough for QA. Simple enough after a long shift.
No stock-photo confidence. VIXAR shows the source, the owner, the timing, and the next action so a tired operator can still see what matters.MES x LIMS x QMS x Calibration x EMS x LMS///Export-driven contradiction review///Doctrine-linked verdicts///
[ What It Does ]
It turns messy evidence into a short fix list.
Workbook, photo, and intake answers go in. A score, issue list, and next action come out.
Workbook Scan
Checks tracker exports for missing owners, stale dates, status drift, and contradictions.
Review Routing
Sends the finding to the teammate who knows what question should be asked next.
Doctrine Logic
The product keeps the deep doctrine under the hood and explains findings in plain language.
Room Photo Review
Upload one image. Vision checks whether the room state looks defensible.
Forge Persona
Premium teams encode their own SME review logic as a private persona with rules, boundaries, and source systems.
[ Elsa Readiness ]
FDA upgraded the reviewer. VIXAR upgrades your prep.
FDA announced Elsa 4.0 and HALO on May 6, 2026. HALO consolidates 40+ application and submission data sources; Elsa adds custom agents, document generation, quantitative analysis, text extraction, and optimized search.
Do not walk into AI-assisted review with invisible contradictions across your own trackers, photos, and profile answers.
Workbook scans, clean-room reviews, profile answers, doctrine tags, visibility events, owners, and next actions are recorded before escalation.
Your company can encode a private SME lens: what it reviews, what it must never claim, what systems it knows, and when to route a finding.
Read the FDA release. This is the buyer-facing proof moment: FDA is consolidating the review surface. VIXAR prepares your internal evidence before it gets compared.
[ Visibility Layer ]
Make the issue visible before it becomes expensive.
QUIZ
What does not reconcile?
XLSX
Workbook evidence
PHOTO
Clean-room state
CORE
VISIBILITY
WHO / WHEN / PROOF / NEXT
Who sees it?
Named owner, reviewer, and accountable function
When does it appear?
Execution, review, inspection, or release decision
What proves it?
Workbook cell, photo signal, profile answer, doctrine tag
What happens next?
Fix, review, route, hold for evidence, or request access
OWNER
Who acts?
WHEN
Where it surfaces
NEXT
What unlocks review
[ Review Team ]
Meet your team. Pick the person for the problem.
Each teammate has one job. Pick one, ask the question, and move the review forward.
Adele the Auditor
Show me the row, the source system, and the Truth number. If it cannot be defended, we mark it as an issue.
Arden the Architect
This is not a dashboard problem. The entity model is split across systems, so first we name the canonical field and owner.
Tess the Timeline Keeper
The question is not only what happened. The question is whether the order of evidence still supports the release decision.
Cora the Conductor
Do not fix everything at once. Route the contradiction, assign the owner, then decide what evidence unlocks the next action.
Sage the Advisor
If this becomes an enforcement claim, validation scope changes. Keep the operating boundary explicit before anyone treats it as control logic.
[ 11 Laws ]
Click a law. See what it checks.
You do not need to read the doctrine to use the product. These cards show the operating laws in plain language and link to the deeper records.
Used to explain why a finding matters.
Used to route findings to the right review lens.
Used to decide what must be fixed first.
VIXAR names what is not defensible. It does not release, hold, or enforce.
LAW 01
Inspection Outcome Alignment
Use this law when the issue touches success, criteria, inspection.
successcriteriainspection
LAW 02
Manufacturing Constraint Timeline
Use this law when the issue touches timeline, schedule, manufacturing.
timelineschedulemanufacturing
LAW 03
Escalation and Deviation Triage
Use this law when the issue touches escalation, deviation, triage.
escalationdeviationtriage
LAW 04
Ownership and Accountability
Use this law when the issue touches owner, ownership, accountability.
ownerownershipaccountability
LAW 05
Risk-to-Release Milestones
Use this law when the issue touches risk, matrix, release.
riskmatrixrelease
LAW 06
Readiness Visibility
Use this law when the issue touches readiness, dashboard, green.
readinessdashboardgreen
LAW 07
Embedded Site Operators
Use this law when the issue touches operator, training, frontline.
operatortrainingfrontline
LAW 08
Contingency Boundaries
Use this law when the issue touches contingency, backup, boundary.
contingencybackupboundary
LAW 09
Tech Transfer Spine
Use this law when the issue touches tech transfer, transfer, scope.
tech transfertransferscope
LAW 10
Documented Evidence Control
Use this law when the issue touches document, undocumented, proof.
documentundocumentedproof
LAW 11
Cross-SOR State Contradiction
Use this law when the issue touches system, systems, data.
systemsystemsdata
[ Exposure Before Inspection ]
Expose the weak point before someone else does.
Exposure is the product promise, not a UI mode. VIXAR makes hidden contradictions visible, cites the source of concern, and routes the next question before the finding becomes an inspection-room surprise.
Show the contradiction, owner, timing, and evidence source in plain language.
Anchor the finding to a workbook cell, room signal, profile answer, doctrine tag, or system relationship.
Send the question to the review persona that can decide what proof unlocks the next action.
VIXAR does not release, hold, validate, or write to systems of record. It tells you what needs review.
[ Buyer Questions ]
Questions a regulatory leader asks before trusting the workflow.
These answers keep VIXAR in the evidence-readiness lane: serious, compatible, and impossible to confuse with generic drafting software.
No. VIXAR starts export-first. It reviews evidence from the systems you already use and records the contradiction map without writing back to systems of record.
No. VIXAR prepares the evidence layer before submission assembly. It can support the regulatory team by showing what needs to reconcile before package review.
Submission workspaces manage drafting, review, validation, and package flow. VIXAR detects whether the underlying manufacturing and QA evidence is defensible before that package is built.
Yes. Start with the sanitized workbook demo and guided intake. Real customer records should move behind authorized access and agreed confidentiality boundaries.
Upload one facility image. A vision-capable provider reviews visible room state, while local image metrics and readable text support the finding. Readable text is secondary.
No. VIXAR exposes non-defensible evidence states, names owners, and routes next actions. It does not release, hold, validate, enforce, or replace quality judgment.
VIXAR builds the internal evidence map before FDA-side AI can compare submission data against broader records, patterns, and historical signals.
Yes. Forge Persona lets approved enterprise operators encode private SME rules, source systems, boundaries, tone, and route triggers.
[ Value Ladder ]
Clear next step. No mystery funnel.
Visitors start with sanitized demo evidence. Real operators move into scoped reviews only after trust, access, and data boundaries are clear.
Free Demo
Email-gated sample workbook modeled on common pharma tracker exports.
Public lead captureStarter Review
Request a focused review for one workbook, one room photo, and a short issue register.
Inquire for accessDay Zero Structural Scale
One site, one decision class, cross-SOR contradiction sweep, and executive brief.
Inquire for pilot scopeOn-Site Consultation
Facilitated site review, operating model work, and evidence-routing changes.
Premium scopeForge Persona
Private company personas for regulatory, QA, manufacturing, or site-specific review logic.
Enterprise differentiator[ Trust Package ]
Start sanitized. Move real data behind access.
Trust is part of the product. VIXAR separates public demo data, authorized operator access, confidential evidence review, and human decision ownership.
Public users start with a sanitized tracker package, not proprietary records.
Real workbooks, photos, and profile details belong behind allowlisted operator access and agreed confidentiality terms.
Operators do not bring their own API keys. Provider configuration is controlled by VIXAR admin/IT.
VIXAR does not release, hold, validate, publish, or replace quality judgment.
Start with the five questions.
Then scan the workbook, upload one room photo, and see the next action.
Run Day Zero Intake Patent Pending. Exposure before inspection; no release, hold, or enforcement authority.